Surgical Treatment of Primary Cardiac Paragangliomas: A Single-Center Experience
DOI:
https://doi.org/10.1532/hsf.4255Keywords:
cardiac paraganglioma, cardiac tumor, surgeryAbstract
Background: Cardiac paragangliomas are rare neuroendocrine tumors that will cause significant morbidity if left undiagnosed. Because of the paucity of cohort data, their rapid diagnosis and appropriate management still pose unique challenges to cardiac surgeons. We aimed to investigate the clinical features and surgical management of primary cardiac paragangliomas in our single center.
Methods: From May 2014 to October 2020, patients diagnosed with primary cardiac paragangliomas retrospectively were reviewed. Demographic data, clinical presentation, preoperative imaging methods, surgical resection, perioperative management, histological analysis, and outcomes were recorded. Postoperative follow up also was reviewed.
Results: With multiple imaging methods, including echocardiography, computed tomography, positron-emission tomographic-computed tomography, and biochemical tests, there were five cases of primary cardiac paraganglioma verified by postoperative immunohistochemical staining, two of which were hormonally active. There were no metastatic cardiac paragangliomas, according to positron-emission tomographic-computed tomography, and all patients accepted surgical treatment. Preoperative adrenoceptor blockade was given to hormonally active patients, accordingly. Complete resection of the tumor was accomplished under cardiopulmonary bypass in each case. Tumor distribution included two masses on the roof of the left atrium, two masses in the right atrioventricular groove, and one between the ascending aorta and main pulmonary artery. Immunohistochemical staining for chromogranin, neuron-specific enolase, synaptophysin, and S-100 were positive, which were typical of cardiac paraganglioma. There were no operative deaths. All the patients had an uneventful recovery except one patient who underwent low cardiac output syndrome. During follow up (mean 4.2 years, range 0.6-7.0 years), all patients were well with New York Heart Association class I or II. Only one patient developed thyroid carcinoma three years after surgery but with no paraganglioma recurrence during periodic computed tomography, and this patient recovered well after thyroidectomy.
Conclusion: Although cardiac paragangliomas are rare and may present surgical challenges for clinicians, surgical resection remains the choice of treatment with favorable outcomes through a multidisciplinary heart team. Moreover, lifelong surveillance still is recommended to detect possible recurrence or associated nonchromaffin tumors in time.
References
Bravo EL, Tagle R. 2003. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 24:539-553.
Brown ML, Zayas GE, Abel MD, et al. 2008. Mediastinal paragangliomas: the mayo clinic experience. Ann Thorac Surg. 86: 946-951.
Chen H, Sippel RS, O’Dorisio MS, et al. 2010. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 39:775-783.
Erickson D, Kudva YC, Ebersold MJ, et al. 2001. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 86:5210-5216.
Han S, Suh CH, Woo S, et al. 2019. Performance of 68GaDOTAconjugated somatostatin receptortargeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med. 60: 369376.
Hardegree EL, Patel SM, Maleszewski JJ, et al. 2012. The heart of the matter. Am J Med. 125:873-875.
Huo JL, Choi JC, DeLuna A, et al. 2012. Cardiac paraganglioma: diagnostic and surgical challenges. J Card Surg. 27:178-182.
Lam AK-Y, Lam AK. 2017. Update on adrenal tumours in 2017 World Health organization (who) of endocrine tumours. Endocr Pathol. 28:213-227.
Lenders JW, Duh Q-Y, Eisenhofer G, et al. 2014. Pheochromocytoma and paraganglioma: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 99:1915-1942.
Lenders JW, Pacak K, Walther MM, et al. 2002. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 287:1427-1434.
Liu XP, Miao Q, Liu XR, et al. 2019. Outcomes of surgery for functional cardiac paragangliomas: A single-center experience of 17 patients. J Thorac Cardiovasc Surg. 157(4):1556-1564.
Meng Q, Lai H, Lima J, et al. 2002. Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases. Int J Cardiol. 84:69-75.
Plouin PF, Duclos JM, Soppelsa F, et al. 2001. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 86:1480-1486.
Van Slycke S, Caiazzo R, Pigny P, et al. 2009. Local-regional recurrence of sporadic or syndromic abdominal extra-adrenal paraganglioma: incidence, characteristics, and outcome. Surgery. 146:986-992.
Vander Salm TJ. 2000. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 12:89-100.
Wang JG, Han J, Jiang T, et al. 2015. Cardiac paragangliomas. J Card Surg. 30:55-60.
Yadav PK, Baquero GA, Malysz J, et al. 2014. Cardiac Paraganglioma. Circ Cardiovasc Interv. 7:851-856.
Yanagawa B, Mazine A, Chan EY, et al. 2018. Surgery for tumors of the heart. Semin Thorac Cardiovasc Surg. 30(4):385-397.
